Review



ipilimumab anti ctla 4 ctla 4 inhibitor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress ipilimumab anti ctla 4 ctla 4 inhibitor
    Nivolumab combined with ipilimumab activates the TLR4–MyD88–NF‐ κ B pathway, whereas TLR4 or NLRP3 knockdown attenuates apoptosis‐related changes in AC16 cardiomyocytes. (A) The expression of TLR4–MyD88–NF‐ κ B pathway‐related proteins was detected via Western blot. (B–G) The protein expression levels of TLR4, MyD88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β . Single‐drug group: PD‐1, programmed cell death Protein 1; combination drug group: <t>CTLA‐4,</t> cytotoxic T lymphocyte‐associated antigen‐4; NF‐ κ B, nuclear factor kappa‐B; TLR4, Toll‐like Receptor 4. (H) Representative Western blot showing the effects of TLR4 or NLRP3 silencing on apoptosis‐related protein expression in AC16 cardiomyocytes treated with nivolumab combined with ipilimumab. (I–M) Quantification of apoptosis‐related proteins, including NLRP3, Bcl‐2, BAX, cleaved caspase‐3, and caspase‐3. (N) Representative Western blot showing the effects of TLR4 silencing on NLRP3 inflammasome components and TLR4–MyD88–NF‐ κ B pathway‐related proteins. (O–U) Quantification of NLRP3, TLR4, MyD88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β expression levels. Data are presented as mean ± SD from three independent biological replicates ( n = 3). Statistical significance was determined using one‐way ANOVA followed by Dunnett′s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.
    Ipilimumab Anti Ctla 4 Ctla 4 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/Ipilimumab/pmc13106983-54-17-24
    Average 94 stars, based on 7 article reviews
    ipilimumab anti ctla 4 ctla 4 inhibitor - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "Combined Nivolumab and Ipilimumab Therapy Promotes Immune‐Mediated Cardiomyocyte Apoptosis Through TLR4–Myd88–NF‐ Κ b–Driven Activation of the NLRP3 Inflammasome"

    Article Title: Combined Nivolumab and Ipilimumab Therapy Promotes Immune‐Mediated Cardiomyocyte Apoptosis Through TLR4–Myd88–NF‐ Κ b–Driven Activation of the NLRP3 Inflammasome

    Journal: Human Mutation

    doi: 10.1155/humu/8506248

    Nivolumab combined with ipilimumab activates the TLR4–MyD88–NF‐ κ B pathway, whereas TLR4 or NLRP3 knockdown attenuates apoptosis‐related changes in AC16 cardiomyocytes. (A) The expression of TLR4–MyD88–NF‐ κ B pathway‐related proteins was detected via Western blot. (B–G) The protein expression levels of TLR4, MyD88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β . Single‐drug group: PD‐1, programmed cell death Protein 1; combination drug group: CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4; NF‐ κ B, nuclear factor kappa‐B; TLR4, Toll‐like Receptor 4. (H) Representative Western blot showing the effects of TLR4 or NLRP3 silencing on apoptosis‐related protein expression in AC16 cardiomyocytes treated with nivolumab combined with ipilimumab. (I–M) Quantification of apoptosis‐related proteins, including NLRP3, Bcl‐2, BAX, cleaved caspase‐3, and caspase‐3. (N) Representative Western blot showing the effects of TLR4 silencing on NLRP3 inflammasome components and TLR4–MyD88–NF‐ κ B pathway‐related proteins. (O–U) Quantification of NLRP3, TLR4, MyD88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β expression levels. Data are presented as mean ± SD from three independent biological replicates ( n = 3). Statistical significance was determined using one‐way ANOVA followed by Dunnett′s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.
    Figure Legend Snippet: Nivolumab combined with ipilimumab activates the TLR4–MyD88–NF‐ κ B pathway, whereas TLR4 or NLRP3 knockdown attenuates apoptosis‐related changes in AC16 cardiomyocytes. (A) The expression of TLR4–MyD88–NF‐ κ B pathway‐related proteins was detected via Western blot. (B–G) The protein expression levels of TLR4, MyD88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β . Single‐drug group: PD‐1, programmed cell death Protein 1; combination drug group: CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4; NF‐ κ B, nuclear factor kappa‐B; TLR4, Toll‐like Receptor 4. (H) Representative Western blot showing the effects of TLR4 or NLRP3 silencing on apoptosis‐related protein expression in AC16 cardiomyocytes treated with nivolumab combined with ipilimumab. (I–M) Quantification of apoptosis‐related proteins, including NLRP3, Bcl‐2, BAX, cleaved caspase‐3, and caspase‐3. (N) Representative Western blot showing the effects of TLR4 silencing on NLRP3 inflammasome components and TLR4–MyD88–NF‐ κ B pathway‐related proteins. (O–U) Quantification of NLRP3, TLR4, MyD88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β expression levels. Data are presented as mean ± SD from three independent biological replicates ( n = 3). Statistical significance was determined using one‐way ANOVA followed by Dunnett′s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.

    Techniques Used: Knockdown, Expressing, Western Blot

    Nivolumab combined with ipilimumab enhanced the degree of apoptosis and inflammation in mouse cardiomyocytes. (A, B) The expression of the myocardial injury factor BNP was detected via immunofluorescence staining. (C) The expression of the myocardial injury factors BNP and TnT was detected by immunohistochemistry. (D–I) The expression of the cardiac apoptosis‐related proteins BAX, Bcl‐2, cleaved caspase‐3, and caspase‐3 was detected via immunofluorescence staining and Western blot. Single group: PD‐1, programmed cell death Protein 1; combination group: CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4. Data are presented as mean ± SD. Each group consisted of five biological replicates (mice) ( n = 5). Statistical significance was determined using one‐way ANOVA followed by Dunnett′s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.
    Figure Legend Snippet: Nivolumab combined with ipilimumab enhanced the degree of apoptosis and inflammation in mouse cardiomyocytes. (A, B) The expression of the myocardial injury factor BNP was detected via immunofluorescence staining. (C) The expression of the myocardial injury factors BNP and TnT was detected by immunohistochemistry. (D–I) The expression of the cardiac apoptosis‐related proteins BAX, Bcl‐2, cleaved caspase‐3, and caspase‐3 was detected via immunofluorescence staining and Western blot. Single group: PD‐1, programmed cell death Protein 1; combination group: CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4. Data are presented as mean ± SD. Each group consisted of five biological replicates (mice) ( n = 5). Statistical significance was determined using one‐way ANOVA followed by Dunnett′s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.

    Techniques Used: Expressing, Immunofluorescence, Staining, Immunohistochemistry, Western Blot

    Nivolumab combined with ipilimumab enhances the expression of the TLR4–Myd88–NF‐ κ B signaling pathway and NLRP3 in the apoptosis of mouse cardiomyocytes. (A) Western blot analysis of the expression of inflammatory factors in the myocardial tissue of mice in the single drug group and combined drug group. (B–F) The expression levels of NLRP3, ASC, caspase‐1, IL‐18 and IL‐1 β . (G) Western blot analysis of TLR4–MyD88–NF‐ κ B pathway‐related proteins in the myocardial tissue of mice in the single‐drug group and (H–M) combination drug group, including the protein expression levels of TLR4, Myd88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β . Single‐drug group: PD‐1, programmed cell death Protein 1. The combination drugs used were as follows: CTLA‐4, cytotoxic T lymphocyte–associated antigen‐4; NF‐ κ B, nuclear factor kappa‐B; TLR4, Toll‐like Receptor 4; and NLRP3, NOD‐like receptor thermal protein domain associated Protein 3. Data are presented as mean ± SD. Each group consisted of five biological replicates (mice) ( n = 5). Statistical significance was determined using one‐way ANOVA followed by Dunnett’s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.
    Figure Legend Snippet: Nivolumab combined with ipilimumab enhances the expression of the TLR4–Myd88–NF‐ κ B signaling pathway and NLRP3 in the apoptosis of mouse cardiomyocytes. (A) Western blot analysis of the expression of inflammatory factors in the myocardial tissue of mice in the single drug group and combined drug group. (B–F) The expression levels of NLRP3, ASC, caspase‐1, IL‐18 and IL‐1 β . (G) Western blot analysis of TLR4–MyD88–NF‐ κ B pathway‐related proteins in the myocardial tissue of mice in the single‐drug group and (H–M) combination drug group, including the protein expression levels of TLR4, Myd88, NF‐ κ B, p‐NF‐ κ B, IKK β , and p‐IKK β . Single‐drug group: PD‐1, programmed cell death Protein 1. The combination drugs used were as follows: CTLA‐4, cytotoxic T lymphocyte–associated antigen‐4; NF‐ κ B, nuclear factor kappa‐B; TLR4, Toll‐like Receptor 4; and NLRP3, NOD‐like receptor thermal protein domain associated Protein 3. Data are presented as mean ± SD. Each group consisted of five biological replicates (mice) ( n = 5). Statistical significance was determined using one‐way ANOVA followed by Dunnett’s post hoc test for multiple comparisons. p < 0.05; ∗ p < 0.01; ∗∗ p < 0.001; ns, not significant.

    Techniques Used: Expressing, Western Blot

    Related Articles

    CCK-8 Assay:

    Article Title: CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy
    Article Snippet: CIK cells (CP-H228, Procell) were cultured per supplier protocols. .. Immune checkpoint inhibitors Nivolumab (HY-P9903, MCE) and Ipilimumab (HY-P9901, MCE); apoptosis and cell cycle detection kits Annexin V-FITC/PI (CA1020, Solarbio) and DNA Content Assay Kit (CA1510, Solarbio); extracellular matrix component Matrigel (356234, Corning); cell viability reagent CCK-8 Kit (CK04, Dojindo); staining agent Crystal Violet (C8470, Solarbio); and fixation solution 4% Paraformaldehyde (G1113, Servicebio). ..

    Staining:

    Article Title: CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy
    Article Snippet: CIK cells (CP-H228, Procell) were cultured per supplier protocols. .. Immune checkpoint inhibitors Nivolumab (HY-P9903, MCE) and Ipilimumab (HY-P9901, MCE); apoptosis and cell cycle detection kits Annexin V-FITC/PI (CA1020, Solarbio) and DNA Content Assay Kit (CA1510, Solarbio); extracellular matrix component Matrigel (356234, Corning); cell viability reagent CCK-8 Kit (CK04, Dojindo); staining agent Crystal Violet (C8470, Solarbio); and fixation solution 4% Paraformaldehyde (G1113, Servicebio). ..

    other:


    Transplantation Assay:

    Article Title: Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts.
    Article Snippet: .. Six weeks post transplantation mice belonging to group (2) and (3) received an intravenous (IV) injection of 1–5*106 expanded T cells (T cell expanded from the same patients donating CD34+ cells for the PDXs) and began IgG1k or anti-CTLA-4 (Ipilimumab clone) (MedChemExpress) treatment at the same time. ..

    IV Injection:

    Article Title: Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts.
    Article Snippet: .. Six weeks post transplantation mice belonging to group (2) and (3) received an intravenous (IV) injection of 1–5*106 expanded T cells (T cell expanded from the same patients donating CD34+ cells for the PDXs) and began IgG1k or anti-CTLA-4 (Ipilimumab clone) (MedChemExpress) treatment at the same time. ..



    Similar Products

    94
    InvivoGen jurkat cells
    Jurkat Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/CTLA-4%2FCD80+Bio-IC/pm42546824-117-15-18
    Average 94 stars, based on 1 article reviews
    jurkat cells - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology ctla 4
    Ctla 4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/CTLA-4+Antibody/pm42882825-91-9-12
    Average 94 stars, based on 1 article reviews
    ctla 4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Bio X Cell anti ctla4
    Anti Ctla4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/InVivoMAb+anti-mouse+CTLA-4/pm42875546-469-22-30
    Average 96 stars, based on 1 article reviews
    anti ctla4 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Bio X Cell anti ctla 4
    A – E scRNAseq of 80% T Act and 20% T CM /T Naive sorted from the tdLN of 14-day KP-bearing mice (gating strategy in Supplementary Fig. ). A UMAP dimensionality reduction embedding the different clusters. B Dot plot showing the expression of core marker genes across clusters. C Violin plots showing the scoring of indicated gene signatures across activated clusters , , . D Distribution of T Act clusters across CITE-Seq gated CD103 - T Act and CD103 + T Act . E Projection of lung Cd44 + Sell - scRNA-seq clusters 1, 4, 7, 8, and 9 on tdLN T Act clusters 0, 3, 5, and 8. F Representative flow cytometry gating strategy and quantification of the proportions of T Act populations in KP tdLN ( n = 12 mice). Data are presented as stacked mean values ± SD. G Representative flow cytometry histograms and quantifications of SLAMF6, CD49a, and Hobit-tdTomato expression across tdLN T Act subsets ( n = 5 Hobit-tdTomato mice, repeated measures one-way ANOVA with Tukey’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. H Representative flow cytometry gating strategy showing the phenotype of tetramer-OVA + (dark) or tetramer-OVA - cells (grey) in the tdLN of KP-OVA tumor-bearing mice. I Quantification of the proportions of Tet-OVA + or Tet-OVA - CD8 + T cell populations in the tdLN of KP-OVA tumor-bearing mice ( n = 4 mice, repeated measures two-way ANOVA with Šídák’s multiple comparisons test). Data are presented as stacked mean values ± SD. J Quantification of the absolute numbers of Tet-OVA + or Tet-OVA - CD8 + T cell populations in the tdLN of KP-OVA tumor-bearing mice ( n = 4 mice, repeated measures two-way ANOVA with Šídák’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. K Representative flow cytometry plots showing tdLN Tet-OVA + T Act subsets at day 17 post KP-OVA tumor injection and chronic isotype, anti-PD-1, <t>anti-CTLA-4,</t> or combined treatment as depicted in Supplementary Fig. . L Quantifications of the proportions of tdLN Tet-OVA + T Act subsets at day 17 post KP-OVA tumor injection and chronic isotype, anti-PD-1, anti-CTLA-4, or combined treatment as depicted in Supplementary Fig. ( n = 7 mice per group, one-way ANOVA with Tukey’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. KP: ( Kras G12D , p53 -/- ) lung adenocarcinoma; tdLN: tumor-draining lymph node; T Act : activated CD8 + T cell; T RM : tissue-resident memory-like CD8 + T cell; T Ex : exhausted-like CD8 + T cell; T Effector : effector-like CD8 + T cell.
    Anti Ctla 4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/InVivoMAb+anti-mouse+CTLA-4/pmc13680476-531-17-20
    Average 96 stars, based on 1 article reviews
    anti ctla 4 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology anti mouse ctla 4 antibody
    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers <t>(CTLA‐4)</t> on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Anti Mouse Ctla 4 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/CTLA4+Rabbit+pAb/pmc13505587-401-13-19
    Average 94 stars, based on 1 article reviews
    anti mouse ctla 4 antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    97
    InvivoGen non ctla 4 expressing jurkat cells
    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers <t>(CTLA‐4)</t> on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Non Ctla 4 Expressing Jurkat Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/Jurkat-Lucia+NFAT-CD16-Low+Cells/pm42546824-118-0-5
    Average 97 stars, based on 1 article reviews
    non ctla 4 expressing jurkat cells - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec ctla 4
    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers <t>(CTLA‐4)</t> on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Ctla 4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/CD152+Antibody%2C+anti-human%2C+REAfinity/pm42455847-67-91-93
    Average 93 stars, based on 1 article reviews
    ctla 4 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    86
    Agenus Inc protein 4 ctla 4 antibody
    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers <t>(CTLA‐4)</t> on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Protein 4 Ctla 4 Antibody, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/anti+associated+cytotoxic+lymphocyte+t/pm42321949-234-28-29
    Average 86 stars, based on 1 article reviews
    protein 4 ctla 4 antibody - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec cd152 ctla 4 apc
    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers <t>(CTLA‐4)</t> on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Cd152 Ctla 4 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/CD152+Antibody%2C+anti-human/pmc13053985-9-0-7
    Average 93 stars, based on 1 article reviews
    cd152 ctla 4 apc - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    86
    Agenus Inc anticytotoxic t lymphocyte antigen 4 ctla 4 antibody ipilimumab
    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers <t>(CTLA‐4)</t> on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Anticytotoxic T Lymphocyte Antigen 4 Ctla 4 Antibody Ipilimumab, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctla/anti+associated+cytotoxic+lymphocyte+t/pm42314852-49-36-40
    Average 86 stars, based on 1 article reviews
    anticytotoxic t lymphocyte antigen 4 ctla 4 antibody ipilimumab - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    A – E scRNAseq of 80% T Act and 20% T CM /T Naive sorted from the tdLN of 14-day KP-bearing mice (gating strategy in Supplementary Fig. ). A UMAP dimensionality reduction embedding the different clusters. B Dot plot showing the expression of core marker genes across clusters. C Violin plots showing the scoring of indicated gene signatures across activated clusters , , . D Distribution of T Act clusters across CITE-Seq gated CD103 - T Act and CD103 + T Act . E Projection of lung Cd44 + Sell - scRNA-seq clusters 1, 4, 7, 8, and 9 on tdLN T Act clusters 0, 3, 5, and 8. F Representative flow cytometry gating strategy and quantification of the proportions of T Act populations in KP tdLN ( n = 12 mice). Data are presented as stacked mean values ± SD. G Representative flow cytometry histograms and quantifications of SLAMF6, CD49a, and Hobit-tdTomato expression across tdLN T Act subsets ( n = 5 Hobit-tdTomato mice, repeated measures one-way ANOVA with Tukey’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. H Representative flow cytometry gating strategy showing the phenotype of tetramer-OVA + (dark) or tetramer-OVA - cells (grey) in the tdLN of KP-OVA tumor-bearing mice. I Quantification of the proportions of Tet-OVA + or Tet-OVA - CD8 + T cell populations in the tdLN of KP-OVA tumor-bearing mice ( n = 4 mice, repeated measures two-way ANOVA with Šídák’s multiple comparisons test). Data are presented as stacked mean values ± SD. J Quantification of the absolute numbers of Tet-OVA + or Tet-OVA - CD8 + T cell populations in the tdLN of KP-OVA tumor-bearing mice ( n = 4 mice, repeated measures two-way ANOVA with Šídák’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. K Representative flow cytometry plots showing tdLN Tet-OVA + T Act subsets at day 17 post KP-OVA tumor injection and chronic isotype, anti-PD-1, anti-CTLA-4, or combined treatment as depicted in Supplementary Fig. . L Quantifications of the proportions of tdLN Tet-OVA + T Act subsets at day 17 post KP-OVA tumor injection and chronic isotype, anti-PD-1, anti-CTLA-4, or combined treatment as depicted in Supplementary Fig. ( n = 7 mice per group, one-way ANOVA with Tukey’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. KP: ( Kras G12D , p53 -/- ) lung adenocarcinoma; tdLN: tumor-draining lymph node; T Act : activated CD8 + T cell; T RM : tissue-resident memory-like CD8 + T cell; T Ex : exhausted-like CD8 + T cell; T Effector : effector-like CD8 + T cell.

    Journal: Nature Communications

    Article Title: Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors

    doi: 10.1038/s41467-026-77641-7

    Figure Lengend Snippet: A – E scRNAseq of 80% T Act and 20% T CM /T Naive sorted from the tdLN of 14-day KP-bearing mice (gating strategy in Supplementary Fig. ). A UMAP dimensionality reduction embedding the different clusters. B Dot plot showing the expression of core marker genes across clusters. C Violin plots showing the scoring of indicated gene signatures across activated clusters , , . D Distribution of T Act clusters across CITE-Seq gated CD103 - T Act and CD103 + T Act . E Projection of lung Cd44 + Sell - scRNA-seq clusters 1, 4, 7, 8, and 9 on tdLN T Act clusters 0, 3, 5, and 8. F Representative flow cytometry gating strategy and quantification of the proportions of T Act populations in KP tdLN ( n = 12 mice). Data are presented as stacked mean values ± SD. G Representative flow cytometry histograms and quantifications of SLAMF6, CD49a, and Hobit-tdTomato expression across tdLN T Act subsets ( n = 5 Hobit-tdTomato mice, repeated measures one-way ANOVA with Tukey’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. H Representative flow cytometry gating strategy showing the phenotype of tetramer-OVA + (dark) or tetramer-OVA - cells (grey) in the tdLN of KP-OVA tumor-bearing mice. I Quantification of the proportions of Tet-OVA + or Tet-OVA - CD8 + T cell populations in the tdLN of KP-OVA tumor-bearing mice ( n = 4 mice, repeated measures two-way ANOVA with Šídák’s multiple comparisons test). Data are presented as stacked mean values ± SD. J Quantification of the absolute numbers of Tet-OVA + or Tet-OVA - CD8 + T cell populations in the tdLN of KP-OVA tumor-bearing mice ( n = 4 mice, repeated measures two-way ANOVA with Šídák’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. K Representative flow cytometry plots showing tdLN Tet-OVA + T Act subsets at day 17 post KP-OVA tumor injection and chronic isotype, anti-PD-1, anti-CTLA-4, or combined treatment as depicted in Supplementary Fig. . L Quantifications of the proportions of tdLN Tet-OVA + T Act subsets at day 17 post KP-OVA tumor injection and chronic isotype, anti-PD-1, anti-CTLA-4, or combined treatment as depicted in Supplementary Fig. ( n = 7 mice per group, one-way ANOVA with Tukey’s multiple comparisons test). Data are presented as mean values ± SD with individual replicates displayed. KP: ( Kras G12D , p53 -/- ) lung adenocarcinoma; tdLN: tumor-draining lymph node; T Act : activated CD8 + T cell; T RM : tissue-resident memory-like CD8 + T cell; T Ex : exhausted-like CD8 + T cell; T Effector : effector-like CD8 + T cell.

    Article Snippet: For chronic ICB immunotherapies, mice received intraperitoneal injections of 200 μg control isotype (clone 2A3, BioXCell BE0089), anti-CTLA-4 (clone 9H10, BioXCell BE0131), anti-PD-1 (clone 29F.1A12, BioxCell BE0273), or both anti-PD-1 and anti-CTLA-4 antibodies in 200 μl of PBS every 3 days from day 7 after KP-OVA tumor injection and mice were euthanized at day 17 for T cell analysis.

    Techniques: Expressing, Marker, Flow Cytometry, Injection, Tissue

    Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers (CTLA‐4) on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Advanced Science

    Article Title: Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8 + T Cells by Inhibiting S100A8/A9‐CD36 Axis in Obesity‐Associated Pancreatic Adenocarcinoma

    doi: 10.1002/advs.202515759

    Figure Lengend Snippet: Cell–cell communication analysis indicated that S100a8/a9 served as a critical target for coixenolide, regulating the interactions between PAAD cells and CD8 + T cells. (A) The overview of cell–cell interactions between malignant epithelial cells and T cells in the tumor tissues treated with vehicle control and coixenolide, respectively. (B) The intensity of intercellular signaling, showing both the sent and received signals. The cells in the upper right corner exhibit the strongest incoming and outgoing interactions. S100a8/a9 + tumor cell clusters (Clusters 2 and 8) are highlighted in red boxes. Cytotoxic CD8 + T and Treg cells are indicated by red arrows. (C) The outgoing communication patterns of epithelial cells and T cells in the tumor of HFD‐fed mice with or without coixenolide treatment. (D) CD8 + T cell killing assays were conducted using coculture of Pan02 and CD8 + T cells. Pan02 or CD8 + T cells were pretreated with 25 mg/mL coixenolide before coculture. (E) Primary CD8 + T cells were activated by incubation with CD3/CD28 antibody and labeled with carboxy‐fluorescein succinimidyl ester (CFSE). (F–H) The levels of TNF‐α (F), IFN‐γ (G), and Granzyme B (GZMB) (H) in the supernatants after co‐culture of CD8 + T and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) were determined using ELISA. (I–K) The expression of TNF‐α (I), IFN‐γ (J), and Granzyme B (GZMB) (K) in CD8 + T cells after co‐culture of CD8 + T cells and Pan02 cells pretreated with coixenolide (+) or vehicle control (−) was determined using flow cytometry. (L) Flow cytometry analyses of T cell exhaustion markers (CTLA‐4) on CD8 + T cells after coculture of Pan02 and CD8 + T cells pretreated with coixenolide (+) or vehicle control (−). (M,N) Flow cytometry analyses of CD8 + T cell killing (M) and division (N) activities. CD8 + T cells were cocultured with S100a9 knockout (KO) or wild‐type (WT) Pan02 cells. (O–Q) The levels of TNF‐α (O), IFN‐γ (P), and GZMB (Q) in the supernatants after coculture of CD8 + T cells with WT or S100a9 KO Pan02 cells were determined using ELISA. n = 3 or 4 independent coculture experiments or replicates. One‐way ANOVA with Tukey's post‐hoc test (E–L), two‐sided t ‐test (M–N), or two‐way ANOVA (O‐Q) was used. All p values are two‐sided. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Following treatment with coixenolide for 24 h, Treg cells were stained with PE‐conjugated anti‐mouse CTLA‐4 antibody ( A27774 , ABclonal) and FITC‐conjugated anti‐mouse IL‐10 antibody ( A27680 , ABclonal), and the expression levels of CTLA‐4 and IL‐10 were analyzed by flow cytometry.

    Techniques: Control, Incubation, Labeling, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Expressing, Flow Cytometry, Knock-Out